Home/Filings/4/0001415889-23-012126
4//SEC Filing

Pontes Josias 4

Accession 0001415889-23-012126

CIK 0001821323other

Filed

Aug 10, 8:00 PM ET

Accepted

Aug 11, 4:10 PM ET

Size

8.8 KB

Accession

0001415889-23-012126

Insider Transaction Report

Form 4
Period: 2023-08-11
Pontes Josias
VP, Head of Finance
Transactions
  • Disposition to Issuer

    Common Stock

    2023-08-113,5040 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-08-11$0.75/sh10,767$8,0750 total
    Exercise: $14.17Exp: 2033-02-27Common Stock (10,767 underlying)
Footnotes (4)
  • [F1]Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share.
  • [F2]Includes 250 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase period from April 3, 2023 to August 3, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock. This transaction is exempt under Rule 16b-3(c).
  • [F3]Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
  • [F4]Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time.

Issuer

Sigilon Therapeutics, Inc.

CIK 0001821323

Entity typeother

Related Parties

1
  • filerCIK 0001868415

Filing Metadata

Form type
4
Filed
Aug 10, 8:00 PM ET
Accepted
Aug 11, 4:10 PM ET
Size
8.8 KB